ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience

MADRID, SPAIN and CAMBRIDGE MA.

• ORY-2001 reduces aggression in animal models

• The drug also reduces social withdrawal

• ORY-2001 proposed to restore cognitive function and treat behavioral alterations frequently associated with Alzheimer’s disease patients

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has presented today new preclinical data on its investigational drug ORY-2001, a selective LSD1-MAOB dual inhibitor, at the SfN’s 47th annual meeting (Neuroscience 2017), being held at the Walter E. Washington Convention Center, Washington DC (USA) in November 11-15. The communication, presented as Poster nº 336.09 at the “Cortical Systems and Mechanisms of Disease” Session and entitled “ORY-2001, a dual LSD1/MAOB inhibitor in development for neurodegenerative diseases, normalizes aggressive behavior in SAMP-8 mice and social avoidance in isolated rats” was presented by neuroscientists from the company accompanied by the Medical Director, Dr. Roger Bullock.

Click here to see the full Press Release